Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?
Johnson & Johnson (NYSE: JNJ) reported its Q3 results last week, with revenues and earnings beating the street estimates.
Source: forbes.com
Stay updated with breaking news from Johnson Amp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Johnson & Johnson (NYSE: JNJ) reported its Q3 results last week, with revenues and earnings beating the street estimates.
Bond yields show signs they may have peaked, making a host of stocks look attractive.
Procter & Gamble, Clorox, and Kenvue are among the standouts in a beaten-down sector. They boast healthy dividends and resilient businesses.
It's been a tough year for the sector.
Johnson & Johnson MedTech executive vice president and worldwide chair is stepping down, the company said Oct. 23.